Biotech Values

[Bio_pete]

re: JAV

Its my understanding that a lot of pressure has been placed on the new management to find a buy-out offer. They keep changing the game plan every few months, but this looks like the best case scenario. Top-line data on Dyloject's Phase III will be reported late 3rd qtr. The company will then hire a bank to solicit offers. If they can't find a buyer then it will look like another MBRK.

I predict the company will report less then $200K for Dyloject sales in the 2nd qtr & the stock may break $2 a share. The stock should trend back to the $2.50 area as we wait for Phase III data (extremely low chance of negative results) and may trade over $3.00 once the results are released.